News

Product differentiation via oral formulations of biologics could be the next battleground between originators and biosimilar companies.

Oral biologics would offer many advantages over injectable drugs, and some companies believe they are on the cusp of making this happen.

With multiple biologics nearing the end of their patent exclusivities, biosimilar developers are branching out.

The random jumble of letters that the FDA attaches to new biologics and biosimilars plays a big role in patient acceptance of these drugs, investigators report.

Results of an analytical similarity test provide additional evidence in support of a biologics license application filed with the FDA by Amgen and Allergan.

This summer, The Center for Biosimilars® interviewed several experts for their opinions on the current need for biosimilars and how companies are working to overcome barriers to uptake. Here are some highlights.

Here are the top 5 biosimilar articles for the week of August 31, 2020.

Multiple studies indicate the nocebo effect is particularly influential in the treatment of inflammatory bowel disease (IBD), according to an opinion piece.

Bio-Thera said it has begun testing the safety its ustekinumab biosimilar in healthy volunteers.

Some European markets are more formidable than others with regard to complexity and getting biosimilars established, but there are good places to start, Jonathan Sweeting, head of Europe for Samsung Bioepis, explains.

Authors of a report on Medicare spending trends said there’s more to controlling the affordability of insulin than instituting out-of-pocket (OOP) caps.

It’s same old, same old when it comes to pharmacy benefit manager (PBM) contracts despite much touted reforms, authors of a review contend.

The Australia-based biosimilar company hopes to compete with blockbuster programmed death-1 (PD-1) inhibitor franchises owned by Merck and Bristol Myers Squibb.

A look at efforts biosimilar manufacturers are taking to develop treatments for coronavirus disease 2019 (COVID-19).

The month of August was replete with clinical trial news and biosimilar launches for the treatment of rheumatic conditions.

Health technology tssessments play an important role in building confidence for use of biosimilars, yet very few meet criteria for thoroughness.

For all intents and purposes, Semglee is a biosimilar insulin, but official biosimilar status is needed to clinch the marketing aspect.

Coronavirus disease 2019 altered the workflow in all areas of the health care and life sciences industries, and the FDA was not exempt from pandemic-induced upheaval.

With the launch of an adalimumab, Cadila hopes to get a piece of the worldwide biosimilar market for antirheumatic treatments.

To help employers achieve biosimilar savings, the Midwest Business Group on Health has created a 13-step action plan.

Here are the top 5 biosimilar articles for the week of August 24, 2020.

Julianna Merten, PharmD, BCPS, BCOP, of Mayo Clinic provides an overview of growth factor biosimilars for pharmacists amid the pandemic.

Two decades of using anti–tumor necrosis factor (TNF) drugs in inflammatory bowel disease (IBD) have answered some questions and left others unanswered.

The Association for Accessible Medicines, which represents generic and biosimilar manufacturers, chose a leader with a research, public relations, and strategic planning background.

The launch marks the first European market entry for Nepexto.

Opinion leaders discuss the significance of regulatory changes affecting biosimilar and insulin products.

A September 29, 2020, symposium with Sonia T. Oskouei, PharmD, BCMAS, DPLA, of Cardinal Health will explore how to incorporate biosimilars into the treatment of inflammatory conditions.

Celltrion Healthcare said it will begin testing its denosumab (Prolia) biosimilar in a phase 1 clinical trial in September.

The statistics show that for the Rocky Mountain province, biosimilar savings are pouring into the health care system and allowing for significantly greater access.